| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone does not have a specific biological target itself but serves as a chemical intermediate for the synthesis of antiviral drugs. Its role is to provide a protected carbohydrate scaffold that can be further modified to produce nucleoside analogs. As a purine nucleoside analogue, the final compounds synthesized from this intermediate can target viral polymerases or other enzymes involved in nucleic acid synthesis.
|
|---|---|
| ln Vitro |
The in vitro activity of 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is assessed by its utility as a synthetic intermediate. The efficiency of its conversion to target compounds, such as Ribavirin, and the purity of the final products are key measures of its utility. The compound itself is not biologically active but serves as a precursor for the synthesis of biologically active molecules.
|
| ln Vivo |
In vivo studies for 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone are conducted on the antiviral drugs synthesized using this intermediate rather than the lactone itself. These drugs, such as Ribavirin, are evaluated in animal models for their pharmacokinetic properties, biodistribution, and therapeutic efficacy against viral infections. The protecting groups are removed during synthesis, and the final drug contains the active nucleoside analog.
|
| Enzyme Assay |
For the synthesis of antiviral drugs, 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is used as a starting material in a multi-step chemical synthesis. The compound is typically converted to the corresponding nucleoside analog through a series of reactions, including glycosylation, deprotection, and functional group modifications. The progress of the synthesis is monitored by TLC, HPLC, or NMR.
|
| Cell Assay |
For cellular studies, the antiviral drugs synthesized using 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone are tested in cell-based assays. Cells infected with viruses are treated with the drugs, and viral replication is assessed by measuring viral RNA or protein levels. The drugs' ability to inhibit viral replication and their cytotoxicity are evaluated.
|
| Animal Protocol |
For in vivo evaluation of antiviral drugs, mice or rats are infected with viruses and administered the drugs via various routes. Pharmacokinetic parameters including half-life, clearance, and tissue distribution are determined. For therapeutic applications, efficacy is evaluated by measuring viral load, survival, and histopathological analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone are characterized for the antiviral drugs incorporating this building block rather than the intermediate itself. The compound has a molecular weight of 418.48. It is typically handled as a crystalline solid and stored under recommended conditions to maintain stability. Detailed PK parameters depend on the specific antiviral drug synthesized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is not explicitly detailed in the provided sources. As a chemical intermediate, standard laboratory safety precautions should be followed when handling it. It is intended for research use only and is not for human therapeutic applications. The compound's safety would be evaluated in the context of the final drug product rather than the intermediate itself.
|
| References | |
| Additional Infomation |
2,3,5-Tri-O-benzyl-D-ribono-1,4-lactone is a protected carbohydrate lactone with a molecular formula of C26H26O5 and a molecular weight of 418.48. It is a key intermediate in the synthesis of antiviral drugs such as Ribavirin. This research compound is for laboratory use only and has not been approved for clinical applications.
|
| Molecular Formula |
C26H26O5
|
|---|---|
| Molecular Weight |
418.48
|
| Exact Mass |
418.178
|
| CAS # |
55094-52-5
|
| PubChem CID |
11004289
|
| Appearance |
White to off-white solid powder
|
| Density |
1.21±0.1 g/cm3
|
| Boiling Point |
576.8±50.0 °C
|
| Melting Point |
54-55 °C
|
| LogP |
4.299
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
31
|
| Complexity |
520
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1=CC=C(C=C1)COC[C@@H]2[C@H]([C@H](C(=O)O2)OCC3=CC=CC=C3)OCC4=CC=CC=C4
|
| InChi Key |
LDHBSABBBAUMCZ-UBFVSLLYSA-N
|
| InChi Code |
InChI=1S/C26H26O5/c27-26-25(30-18-22-14-8-3-9-15-22)24(29-17-21-12-6-2-7-13-21)23(31-26)19-28-16-20-10-4-1-5-11-20/h1-15,23-25H,16-19H2/t23-,24-,25-/m1/s1
|
| Chemical Name |
(3R,4R,5R)-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (238.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3896 mL | 11.9480 mL | 23.8960 mL | |
| 5 mM | 0.4779 mL | 2.3896 mL | 4.7792 mL | |
| 10 mM | 0.2390 mL | 1.1948 mL | 2.3896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
